- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 493/08 - Bridged systems
Patent holdings for IPC class C07D 493/08
Total number of patents in this class: 888
10-year publication summary
|
85
|
58
|
63
|
86
|
73
|
56
|
60
|
61
|
52
|
42
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| VALO Health, Inc. | 172 |
37 |
| Novartis AG | 10867 |
21 |
| Lixte Biotechnology, Inc. | 64 |
21 |
| Pfizer Inc. | 3379 |
14 |
| Eisai R&D Management Co., Ltd. | 1238 |
14 |
| President and Fellows of Harvard College | 5966 |
12 |
| BASF Agro B.V. | 198 |
12 |
| Vanderbilt University | 1894 |
12 |
| Gilead Sciences, Inc. | 2032 |
11 |
| JNC Corporation | 1552 |
11 |
| Syngenta Limited | 457 |
10 |
| JNC Petrochemical Corporation | 401 |
10 |
| Bristol-myers Squibb Company | 4878 |
9 |
| Abbvie Inc. | 1803 |
9 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2845 |
9 |
| F. Hoffmann-La Roche AG | 7929 |
8 |
| Janssen Pharmaceutica N.V. | 3399 |
8 |
| Purdue Research Foundation | 3583 |
8 |
| Sunshine Lake Pharma Co., Ltd. | 597 |
8 |
| Guangxi Jiufu Biotechnology Co., Ltd | 13 |
8 |
| Other owners | 636 |